Wealthcare Advisory Partners’s Sage Therapeutics SAGE Stock Holding History

Wealthcare Advisory Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-300	Closed	-$22K	–	1615
2021 Q1	$22K	Buy	+300	New	+$24.6K	﹤0.01%	1177
2020 Q2	–	Sell	-300	Closed	-$9K	–	1149
2020 Q1	$9K	Hold	300	–	–	﹤0.01%	956
2019 Q4	$22K	Buy	300 +50	+20%	+$6.15K	﹤0.01%	746
2019 Q3	$35K	Buy	250 +150	+150%	+$25.1K	0.01%	616
2019 Q2	$18K	Buy	+100	New	+$17.1K	﹤0.01%	754

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wealthcare Advisory Partners's SAGE Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 300 shares — an estimated $22K sold.

Wealthcare Advisory Partners first reported a position in SAGE in Q2 2019 and held it in 5 quarters. The position peaked at $35K in Q3 2019. 257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 300 Sage Therapeutics shares in Q2 2021, an estimated $22K.
Wealthcare Advisory Partners first reported a position in Sage Therapeutics in Q2 2019 and held it in 5 quarters.
Wealthcare Advisory Partners's Sage Therapeutics position peaked at $35K in Q3 2019.
257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.